These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 34686489)

  • 21. Effective Targeting of TAG72
    Murad JP; Kozlowska AK; Lee HJ; Ramamurthy M; Chang WC; Yazaki P; Colcher D; Shively J; Cristea M; Forman SJ; Priceman SJ
    Front Immunol; 2018; 9():2268. PubMed ID: 30510550
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bispecific chimeric antigen receptors targeting the CD4 binding site and high-mannose Glycans of gp120 optimized for anti-human immunodeficiency virus potency and breadth with minimal immunogenicity.
    Ghanem MH; Bolivar-Wagers S; Dey B; Hajduczki A; Vargas-Inchaustegui DA; Danielson DT; Bundoc V; Liu L; Berger EA
    Cytotherapy; 2018 Mar; 20(3):407-419. PubMed ID: 29306566
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multispecific Targeting with Synthetic Ankyrin Repeat Motif Chimeric Antigen Receptors.
    Balakrishnan A; Rajan A; Salter AI; Kosasih PL; Wu Q; Voutsinas J; Jensen MC; Plückthun A; Riddell SR
    Clin Cancer Res; 2019 Dec; 25(24):7506-7516. PubMed ID: 31548346
    [TBL] [Abstract][Full Text] [Related]  

  • 24. IFNγ-Dependent Interactions between ICAM-1 and LFA-1 Counteract Prostaglandin E2-Mediated Inhibition of Antitumor CTL Responses.
    Basingab FS; Ahmadi M; Morgan DJ
    Cancer Immunol Res; 2016 May; 4(5):400-11. PubMed ID: 26928462
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intercellular Adhesion Molecule-1 as Target for CAR-T-Cell Therapy of Triple-Negative Breast Cancer.
    Wei H; Wang Z; Kuang Y; Wu Z; Zhao S; Zhang Z; Li H; Zheng M; Zhang N; Long C; Guo W; Nie C; Yang H; Tong A
    Front Immunol; 2020; 11():573823. PubMed ID: 33072116
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Significantly increased anti-tumor activity of carcinoembryonic antigen-specific chimeric antigen receptor T cells in combination with recombinant human IL-12.
    Chi X; Yang P; Zhang E; Gu J; Xu H; Li M; Gao X; Li X; Zhang Y; Xu H; Hu J
    Cancer Med; 2019 Aug; 8(10):4753-4765. PubMed ID: 31237116
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Epigenetic Priming of Bladder Cancer Cells With Decitabine Increases Cytotoxicity of Human EGFR and CD44v6 CAR Engineered T-Cells.
    Grunewald CM; Haist C; König C; Petzsch P; Bister A; Nößner E; Wiek C; Scheckenbach K; Köhrer K; Niegisch G; Hanenberg H; Hoffmann MJ
    Front Immunol; 2021; 12():782448. PubMed ID: 34868059
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Enhanced CAR-T activity against established tumors by polarizing human T cells to secrete interleukin-9.
    Liu L; Bi E; Ma X; Xiong W; Qian J; Ye L; Su P; Wang Q; Xiao L; Yang M; Lu Y; Yi Q
    Nat Commun; 2020 Nov; 11(1):5902. PubMed ID: 33214555
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chimeric Antigen Receptor T Cell Therapy Targeting ICAM-1 in Gastric Cancer.
    Jung M; Yang Y; McCloskey JE; Zaman M; Vedvyas Y; Zhang X; Stefanova D; Gray KD; Min IM; Zarnegar R; Choi YY; Cheong JH; Noh SH; Rha SY; Chung HC; Jin MM
    Mol Ther Oncolytics; 2020 Sep; 18():587-601. PubMed ID: 32995483
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antitumor activity of EGFR-specific CAR T cells against non-small-cell lung cancer cells in vitro and in mice.
    Li H; Huang Y; Jiang DQ; Cui LZ; He Z; Wang C; Zhang ZW; Zhu HL; Ding YM; Li LF; Li Q; Jin HJ; Qian QJ
    Cell Death Dis; 2018 Feb; 9(2):177. PubMed ID: 29415996
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Improved survival of chimeric antigen receptor-engineered T (CAR-T) and tumor-specific T cells caused by anti-programmed cell death protein 1 single-chain variable fragment-producing CAR-T cells.
    Nakajima M; Sakoda Y; Adachi K; Nagano H; Tamada K
    Cancer Sci; 2019 Oct; 110(10):3079-3088. PubMed ID: 31432594
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antitumor efficacy of chimeric antigen receptor T cells against EGFRvIII-expressing glioblastoma in C57BL/6 mice.
    Chen M; Sun R; Shi B; Wang Y; Di S; Luo H; Sun Y; Li Z; Zhou M; Jiang H
    Biomed Pharmacother; 2019 May; 113():108734. PubMed ID: 30849636
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ICAM-1 expression by lung cancer cell lines: effects of upregulation by cytokines on the interaction with LAK cells.
    Melis M; Spatafora M; Melodia A; Pace E; Gjomarkaj M; Merendino AM; Bonsignore G
    Eur Respir J; 1996 Sep; 9(9):1831-8. PubMed ID: 8880099
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Analysis of Antitumor Effects of CAR-T Cells in Mice with Solid Tumors.
    Rodriguez-Garcia A; Watanabe K; Guedan S
    Methods Mol Biol; 2020; 2086():251-271. PubMed ID: 31707682
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combination Therapy with EpCAM-CAR-NK-92 Cells and Regorafenib against Human Colorectal Cancer Models.
    Zhang Q; Zhang H; Ding J; Liu H; Li H; Li H; Lu M; Miao Y; Li L; Zheng J
    J Immunol Res; 2018; 2018():4263520. PubMed ID: 30410941
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Low-Dose IFNγ Induces Tumor Cell Stemness in Tumor Microenvironment of Non-Small Cell Lung Cancer.
    Song M; Ping Y; Zhang K; Yang L; Li F; Zhang C; Cheng S; Yue D; Maimela NR; Qu J; Liu S; Sun T; Li Z; Xia J; Zhang B; Wang L; Zhang Y
    Cancer Res; 2019 Jul; 79(14):3737-3748. PubMed ID: 31085700
    [TBL] [Abstract][Full Text] [Related]  

  • 37. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 38. HIV-1-Specific Chimeric Antigen Receptor T Cells Fail To Recognize and Eliminate the Follicular Dendritic Cell HIV Reservoir
    Ollerton MT; Berger EA; Connick E; Burton GF
    J Virol; 2020 May; 94(10):. PubMed ID: 32161179
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Disruption of adenosine 2A receptor improves the anti-tumor function of anti-mesothelin CAR T cells both in vitro and in vivo.
    Liu G; Zhang Q; Liu G; Li D; Zhang L; Gu Z; Tian H; Zhang Y; Tian X
    Exp Cell Res; 2021 Dec; 409(1):112886. PubMed ID: 34673000
    [TBL] [Abstract][Full Text] [Related]  

  • 40. ShRNA-mediated silencing of PD-1 augments the efficacy of chimeric antigen receptor T cells on subcutaneous prostate and leukemia xenograft.
    Zhou JE; Yu J; Wang Y; Wang H; Wang J; Wang Y; Yu L; Yan Z
    Biomed Pharmacother; 2021 May; 137():111339. PubMed ID: 33550044
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.